tezosentan has been researched along with mocetinostat in 3 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (mocetinostat) | Trials (mocetinostat) | Recent Studies (post-2010) (mocetinostat) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 21,735 | 390 | 8,606 |
| Protein | Taxonomy | tezosentan (IC50) | mocetinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.7851 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.022 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.57 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.102 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.102 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.3433 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3537 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.6386 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.6725 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.5717 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.6725 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barriere, E; Cazals-Hatem, D; Guimont, MC; Lebrec, D; Martin, A; Moreau, R; Poirel, O; Sogni, P; Tazi, KA; Urbanowicz, W | 1 |
| Akbiyik, F; Atilla, P; Balkanci, ZD; Cakar, N; Erdem, A; Guc, MO; Iskit, AB; Meltem Sevgili, A | 1 |
| Ceylan, BG; Gulmen, S; Kiris, I; Mermi, B; Meteoglu, I; Narin, C; Sutcu, R | 1 |
3 other study(ies) available for tezosentan and mocetinostat
| Article | Year |
|---|---|
Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats.
Topics: Animals; Endothelin Receptor Antagonists; Endothelins; Endotoxemia; Lipopolysaccharides; Liver; Liver Cirrhosis; Male; Neutrophil Infiltration; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxidase; Pyridines; Rats; Rats, Sprague-Dawley; Tetrazoles; Transaminases; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2004 |
Tezosentan attenuates organ injury and mesenteric blood flow decrease in endotoxemia and cecal ligation and puncture.
Topics: Animals; Endothelin Receptor Antagonists; Endotoxemia; Kidney; Liver; Mice; Peroxidase; Pyridines; Shock, Septic; Splanchnic Circulation; Spleen; Tetrazoles | 2007 |
Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats.
Topics: Acute Kidney Injury; Animals; Aorta, Abdominal; Aortic Diseases; Catalase; Endothelin Receptor Antagonists; Female; Kidney Glomerulus; Lipid Peroxidation; Male; Malondialdehyde; Necrosis; Oxidative Stress; Peroxidase; Postoperative Complications; Pyridines; Rats; Rats, Wistar; Reperfusion Injury; Superoxide Dismutase; Tetrazoles; Vasodilator Agents | 2009 |